Sequencing Novel Agents in Frontline and Second-Line Treatment of Hodgkin Lymphoma

被引：0
|
作者：
Moskowitz, Alison J. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
Brentuximab vedotin; nivolumab; pembrolizumab; Hodgkin lymphoma; BRENTUXIMAB VEDOTIN; SINGLE-CENTER; CHEMOTHERAPY; CARBOPLATIN; ETOPOSIDE; THERAPY; STAGE;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S101 / S103
页数：3
相关论文
共 50 条
  • [41] Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma
    Hai-Tao Zhao
    Jing Chen
    Sheng-bin Shi
    Jing Tian
    Rong-Jie Tao
    [J]. Medical Oncology, 2015, 32
  • [42] Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
    Herrera, A. F.
    Palmer, J.
    Martin, P.
    Armenian, S.
    Tsai, N-C
    Kennedy, N.
    Sahebi, F.
    Cao, T.
    Budde, L. E.
    Mei, M.
    Siddiqi, T.
    Popplewell, L.
    Rosen, S. T.
    Kwak, L. W.
    Nademanee, A.
    Forman, S. J.
    Chen, R.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (03) : 724 - 730
  • [43] Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma
    Snider, Julia Thornton
    McMorrow, Donna
    Song, Xue
    Diakun, David
    Wade, Sally W.
    Cheng, Paul
    [J]. CLINICAL THERAPEUTICS, 2022, 44 (04) : 521 - +
  • [44] Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma
    Haim, N
    BenShahar, M
    Faraggi, D
    TsuriEtzioni, A
    Leviov, M
    Epelbaum, R
    [J]. CANCER, 1997, 80 (10) : 1989 - 1996
  • [45] Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
    Moskowitz, Alison J.
    Shah, Gunjan
    Schoder, Heiko
    Ganesan, Nivetha
    Hancock, Helen
    Davey, Theresa
    Sohail, Samia
    Santarosa, Alayna
    Pomerantz, Lauren
    Jarjies, Christine
    Galasso, Natasha
    Neuman, Rachel
    Kumar, Anita
    Lahoud, Oscar B.
    Batlevi, Connie Lee
    Hamlin, Paul A.
    Straus, David J.
    Rodriguez-Rivera, Ildefonso
    Owens, Colette
    Caron, Philip
    Intlekofer, Andrew M.
    Hamilton, Audrey
    Horwitz, Steven M.
    Falchi, Lorenzo
    Joffe, Erel
    Palomba, Maria Lia
    Noy, Ariela
    Matasar, Matthew J.
    Pongas, Georgios
    Vardhana, Santosha
    von Keudell, Gottfried R.
    Yahalom, Joachim
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 14 - 15
  • [46] Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
    Moskowitz, Alison J.
    Shah, Gunjan
    Schoder, Heiko
    Ganesan, Nivetha
    Hancock, Helen
    Davey, Theresa
    Sohail, Samia
    Santarosa, Alayna
    Pomerantz, Lauren
    Jarjies, Christine
    Galasso, Natasha
    Neuman, Rachel
    Kumar, Anita
    Lahoud, Oscar B.
    Batlevi, Connie Lee
    Hamlin, Paul A.
    Straus, David J.
    Rodriguez-Rivera, Ildefonso
    Owens, Colette
    Caron, Philip
    Intlekofer, Andrew M.
    Hamilton, Audrey
    Horwitz, Steven M.
    Falchi, Lorenzo
    Joffe, Erel
    Palomba, Maria Lia
    Noy, Ariela
    Matasar, Matthew J.
    Pongas, Georgios
    Vardhana, Santosha
    von Keudell, Gottfried R.
    Yahalom, Joachim
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    [J]. BLOOD, 2020, 136
  • [47] Understanding the differences in outcome between CART studies as second-line treatment in aggressive lymphoma
    Dada, Reyad
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 183 - 190
  • [48] Second-line treatment of diffuse large B-cell lymphoma: Evolution of options
    Fabbri, N.
    Mussetti, A.
    Sureda, A.
    [J]. SEMINARS IN HEMATOLOGY, 2023, 60 (05) : 305 - 312
  • [49] Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma
    Zhao, Hai-Tao
    Chen, Jing
    Shi, Sheng-bin
    Tian, Jing
    Tao, Rong-Jie
    [J]. MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 5
  • [50] Single agents in the second-line treatment of non-small cell lung cancer
    Belani, CP
    [J]. SEMINARS IN ONCOLOGY, 1998, 25 (03) : 10 - 14
12345